Nsaids Linked to IgA-Mediated Hypersensitivity Vasculitis and Purpura Fulminans-Like Eruption.

IgA vasculitis NSAIDs drug hypersensitivity purpura fulminans vasculitis

Journal

European journal of case reports in internal medicine
ISSN: 2284-2594
Titre abrégé: Eur J Case Rep Intern Med
Pays: Italy
ID NLM: 101648453

Informations de publication

Date de publication:
2023
Historique:
received: 24 08 2023
accepted: 04 09 2023
medline: 3 11 2023
pubmed: 3 11 2023
entrez: 3 11 2023
Statut: epublish

Résumé

IgA vasculitis and hypersensitivity reactions following exposure to non-steroidal anti-inflammatory drugs (NSAIDs) are very rarely associated with purpura fulminans (PF). The latter is a coagulation event characterised by decreased levels of protein C and a rapidly progressive purpuric rash, often leading to ischaemia, amputations and death. A previously healthy 66-year-old man presented with a vasculitic rash and abdominal pain following exposure to naproxen (NSAID), which quickly deteriorated to purpura fulminans-like eruption and skin necrosis, mainly involving the face and hands. The presence of IgA sediments on skin biopsy and decreased levels of complement as well as protein C pointed to an immune-mediated inflammatory process. Dramatic clinical escalation with immediate risk to organs and life required an aggressive and broad-spectrum therapeutic approach in an intensive care setting. Clinical improvement and complete reconstitution of protein C were achieved following plasma exchange with fresh frozen plasma (FFP) and immunosuppression with glucocorticoids with no persistent organ damage. This rare case illustrates the catastrophic cross links between NSAIDs, IgA-mediated hypersensitivity vasculitis and purpura fulminans-like syndrome. A high index of suspicion is required for the evaluation of environmental exposures such as drugs and infections in patients with vasculitis and/or purpura. A rapid and comprehensive therapeutic approach should be implemented to avoid multi-organ damage, amputations and death. Complete avoidance of the offending agent is key for future prevention of recurrence. This case illustrates a rare cross link between a commonly used drug (NSAIDs) and severe, life-threatening hypersensitivity reactions (IgA vasculitis and purpura fulminans-like eruption).These events require a high index of suspicion and emphasise the importance of considering environmental exposures such as drugs in the immediate diagnosis of both conditions.In addition to long-term drug avoidance, early and aggressive interventions are required to avoid organ damage, amputations or death.

Sections du résumé

Background UNASSIGNED
IgA vasculitis and hypersensitivity reactions following exposure to non-steroidal anti-inflammatory drugs (NSAIDs) are very rarely associated with purpura fulminans (PF). The latter is a coagulation event characterised by decreased levels of protein C and a rapidly progressive purpuric rash, often leading to ischaemia, amputations and death.
Case summary UNASSIGNED
A previously healthy 66-year-old man presented with a vasculitic rash and abdominal pain following exposure to naproxen (NSAID), which quickly deteriorated to purpura fulminans-like eruption and skin necrosis, mainly involving the face and hands. The presence of IgA sediments on skin biopsy and decreased levels of complement as well as protein C pointed to an immune-mediated inflammatory process. Dramatic clinical escalation with immediate risk to organs and life required an aggressive and broad-spectrum therapeutic approach in an intensive care setting. Clinical improvement and complete reconstitution of protein C were achieved following plasma exchange with fresh frozen plasma (FFP) and immunosuppression with glucocorticoids with no persistent organ damage.
Conclusions UNASSIGNED
This rare case illustrates the catastrophic cross links between NSAIDs, IgA-mediated hypersensitivity vasculitis and purpura fulminans-like syndrome. A high index of suspicion is required for the evaluation of environmental exposures such as drugs and infections in patients with vasculitis and/or purpura. A rapid and comprehensive therapeutic approach should be implemented to avoid multi-organ damage, amputations and death. Complete avoidance of the offending agent is key for future prevention of recurrence.
LEARNING POINTS CONCLUSIONS
This case illustrates a rare cross link between a commonly used drug (NSAIDs) and severe, life-threatening hypersensitivity reactions (IgA vasculitis and purpura fulminans-like eruption).These events require a high index of suspicion and emphasise the importance of considering environmental exposures such as drugs in the immediate diagnosis of both conditions.In addition to long-term drug avoidance, early and aggressive interventions are required to avoid organ damage, amputations or death.

Identifiants

pubmed: 37920231
doi: 10.12890/2023_004072
pii: 4072
pmc: PMC10619524
doi:

Types de publication

Journal Article

Langues

eng

Pagination

004072

Informations de copyright

© EFIM 2023.

Déclaration de conflit d'intérêts

Conflicts of Interests: The Authors declare that there are no competing interests.

Références

Arch Dis Child. 2011 Nov;96(11):1066-71
pubmed: 21233082
Clin Pharmacol Ther. 1981 Aug;30(2):239-45
pubmed: 7249508
Cureus. 2023 Jan 27;15(1):e34270
pubmed: 36855485
N Z Med J. 2022 Feb 3;136(1569):72-76
pubmed: 36726322
JAAD Int. 2022 Jun 13;8:71-78
pubmed: 35721303
Clin Rev Allergy Immunol. 2021 Oct;61(2):181-193
pubmed: 32378145
Semin Immunopathol. 2021 Oct;43(5):729-738
pubmed: 34170395
Transfus Med Rev. 2018 Apr;32(2):69-76
pubmed: 29157918
J Postgrad Med. 2011 Apr-Jun;57(2):145-6
pubmed: 21654144
Autoimmun Rev. 2015 Jul;14(7):579-85
pubmed: 25688001
Autoimmun Rev. 2021 Jan;20(1):102707
pubmed: 33197572

Auteurs

Guy Levenberg (G)

Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Jonathan Bleier (J)

Department of Internal Medicine D, Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel.

Avshalom Leibowitz (A)

Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Department of Internal Medicine D, Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel.

Ophira Salomon (O)

Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Thrombosis and Haemostasis Institute, Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel.

Mudi Misgav (M)

Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Thrombosis and Haemostasis Institute, Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel.

Nancy Agmon-Levin (N)

Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Clinical Immunology, Angioedema and Allergy Institute, Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel.

Ronen Shavit (R)

Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Clinical Immunology, Angioedema and Allergy Institute, Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel.

Classifications MeSH